EMONO
Phase 3Small molecule
EMONO is one of 54 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
3
Indications
4
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
212 competitors in Neuropathic Pain
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaPhase 3
Namenda
AbbViePhase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Briviact
UCBPhase 3
Sativex
Jazz PharmaceuticalsPhase 3
Ultram
WWim Janssens
Phase 3
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Paxil
SSebela Pharmaceuticals Development LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cognitive Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EMONO. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Tours